-
1.发明授权公开(公告)号：US11547705B2
公开(公告)日：2023-01-10
申请号：US15554577
申请日：2016-03-03
Applicant: MERCK SHARP & DOHME LLC , Eisai R&D Management Co., Ltd.
Inventor： Andrew Evan Denker , Yu Kato , Kimiyo Tabata , Yusaku Hori
IPC: A61K39/00 , A61K31/47 , A61K39/395 , A61K45/06 , C07K16/28
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
-
公开(公告)号：US09527921B2
公开(公告)日：2016-12-27
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/32 , A61K33/24 , A61K31/47 , A61K31/337 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够生产包含重链和轻链的可变区以及小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
3.发明授权公开(公告)号：US12083112B2
公开(公告)日：2024-09-10
申请号：US17502962
申请日：2021-10-15
Applicant: MERCK SHARP & DOHME LLC , EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew Evan Denker , Yu Kato , Kimiyo Tabata , Yusaku Hori
IPC: A61K39/00 , A61K31/47 , A61K39/395 , A61K45/06 , C07K16/28
CPC classification number: A61K31/47 , A61K39/39558 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2300/00 , C07K2317/76 , A61K31/47 , A61K2300/00 , A61K39/39558 , A61K2300/00
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):
wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.-
公开(公告)号：US20240271223A1
公开(公告)日：2024-08-15
申请号：US18569317
申请日：2022-04-07
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Megumi KURONISHI , Yu Kato
IPC: C12Q1/6886 , A61K31/47 , A61P35/00
CPC classification number: C12Q1/6886 , A61K31/47 , A61P35/00 , G01N2800/52
Abstract: Biomarkers are provided that predict whether a human subject having a tumor is in need of a therapy comprising an angiogenesis inhibitor (e.g. lenvatinib or a pharmaceutically acceptable salt thereof, such as lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having a tumor.
-
公开(公告)号：US20160347858A1
公开(公告)日：2016-12-01
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了所述小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够产生包含重链和轻链的可变区以及所述小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
Patent Agency Ranking
公开(公告)号：US20160089365A1
公开(公告)日：2016-03-31
申请号：US14862349
申请日：2015-09-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yu Kato , Sho Tachino , Takayuki Nakagawa , Kimiyo Tabata , Kiyoshi Okamoto , Yusaku Hori
IPC: A61K31/47
CPC classification number: A61K31/47
Abstract: An immunostimulatory compound is disclosed.
Abstract translation: 公开了免疫刺激化合物。
-
7.发明授权公开(公告)号：US11147806B2
公开(公告)日：2021-10-19
申请号：US15554577
申请日：2016-03-03
Applicant: MERCK SHARP & DOHME CORP. , Eisai R&D Management Co., Ltd.
Inventor： Andrew Evan Denker , Yu Kato , Kimiyo Tabata , Yusaku Hori
IPC: A61K39/00 , A61K31/47 , A61K39/395 , A61K45/06 , C07K16/28
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
-
公开(公告)号：US09969812B2
公开(公告)日：2018-05-15
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K14/705 , C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , C12N9/14 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
-
9.发明申请公开(公告)号：US20250000853A1
公开(公告)日：2025-01-02
申请号：US18826658
申请日：2024-09-06
Applicant: EISAI R&D MANAGEMENT CO., LTD. , Merck Sharp & Dohme LLC
Inventor： Andrew Evan Denker , Yu Kato , Kimiyo Tabata , Yusaku Hori
IPC: A61K31/47 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/28
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
-
公开(公告)号：US20170096493A1
公开(公告)日：2017-04-06
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.023 seconds)
